Payment overview · 2025
General Payments
$2,179.35
121 reported records · 16 companies
Healthcare provider profile · identity verified
Maximiliano E Hernandez, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PHARR, TX · NPI 1477525384
Verified facts
What the public records show
CMS Open Payments records show Maximiliano E Hernandez, M.D. received $2,179.35 in general payments during 2025 across 121 reported records.
Novo Nordisk Inc accounted for 21.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic, Rexulti, Rybelsus, Shingrix, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 222 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 168 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $478.44 | 21.9% | 27 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $267.18 | 12.3% | 21 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $247.96 | 11.4% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $193.86 | 8.9% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $172.31 | 7.9% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $160.73 | 7.4% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $149.16 | 6.8% | 12 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $112.01 | 5.1% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $88.27 | 4.0% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $79.89 | 3.7% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $67.49 | 3.1% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $46.37 | 2.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $37.01 | 1.7% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $34.13 | 1.6% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.02 | 1.1% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $21.52 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,179.35 | 121 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $385.54 | 19 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $228.88 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $195.53 | 14 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $190.80 | 12 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $172.31 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $172.31 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $152.36 | 12 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $149.63 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $135.91 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $124.12 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $116.79 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $112.01 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $96.44 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $96.44 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $95.26 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $92.90 | 8 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $88.27 | 5 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $73.94 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $67.49 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $67.49 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $37.01 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $34.13 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $24.82 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $23.02 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $21.52 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $18.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 115 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 143 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 75 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 162 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 92 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 222 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 168 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 32 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 12 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 79 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 43 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
92 | 33 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
43 | 11 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
17 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
143 | 46 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
162 | 48 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
79 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
162 | 48 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
222 | 51 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
137 | 37 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
168 | 49 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
32 | 12 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
115 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
41 | 39 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
75 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 995 | 316 |
| Levothyroxine Sodium | Levothyroxine Sodium | 544 | 152 |
| Metformin Hcl | Metformin Hcl | 511 | 176 |
| Gabapentin | Gabapentin | 435 | 160 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 411 | 138 |
| Amlodipine Besylate | Amlodipine Besylate | 385 | 131 |
| Metoprolol Succinate | Metoprolol Succinate | 354 | 116 |
| Lisinopril | Lisinopril | 336 | 108 |
| Losartan Potassium | Losartan Potassium | 332 | 111 |
| Omeprazole | Omeprazole | 332 | 119 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 327 | 136 |
| Montelukast Sodium | Montelukast Sodium | 315 | 115 |
| Famotidine | Famotidine | 274 | 124 |
| Tamsulosin Hcl | Tamsulosin Hcl | 271 | 88 |
| Fluticasone Propionate | Fluticasone Propionate | 267 | 130 |
| Pantoprazole Sodium | Pantoprazole Sodium | 233 | 89 |
| Mounjaro | Tirzepatide | 222 | 51 |
| Sertraline Hcl | Sertraline Hcl | 219 | 81 |
| Azithromycin | Azithromycin | 206 | 166 |
| Simvastatin | Simvastatin | 204 | 65 |
| Clopidogrel | Clopidogrel Bisulfate | 196 | 61 |
| Diclofenac Sodium | Diclofenac Sodium | 187 | 94 |
| Duloxetine Hcl | Duloxetine Hcl | 184 | 64 |
| Bumetanide | Bumetanide | 180 | 61 |
| Celecoxib | Celecoxib | 172 | 69 |
| Potassium Chloride | Potassium Chloride | 169 | 64 |
| Ozempic | Semaglutide | 168 | 49 |
| Jardiance | Empagliflozin | 162 | 48 |
| Alendronate Sodium | Alendronate Sodium | 159 | 53 |
| Memantine Hcl | Memantine Hcl | 155 | 49 |
| Tramadol Hcl | Tramadol Hcl | 154 | 42 |
| Carvedilol | Carvedilol | 149 | 50 |
| Prednisone | Prednisone | 144 | 82 |
| Farxiga | Dapagliflozin Propanediol | 143 | 46 |
| Irbesartan | Irbesartan | 142 | 44 |
| Trulicity | Dulaglutide | 137 | 37 |
| Furosemide | Furosemide | 125 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 124 | 56 |
| Alprazolam | Alprazolam | 122 | 27 |
| Eliquis | Apixaban | 115 | 35 |
| Trazodone Hcl | Trazodone Hcl | 110 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 106 | 32 |
| Buspirone Hcl | Buspirone Hcl | 105 | 40 |
| Nifedipine Er | Nifedipine | 105 | 38 |
| Tradjenta | Linagliptin | 104 | 28 |
| Baclofen | Baclofen | 103 | 42 |
| Meclizine Hcl | Meclizine Hcl | 102 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 32 |
| Pregabalin | Pregabalin | 97 | 40 |
| Cephalexin | Cephalexin | 94 | 72 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 94 | 33 |
| Tresiba Flextouch U-200 | Insulin Degludec | 93 | 30 |
| Linzess | Linaclotide | 92 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 91 | 31 |
| Ibuprofen | Ibuprofen | 91 | 57 |
| Sulfasalazine | Sulfasalazine | 89 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 84 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 83 | 69 |
| Mirtazapine | Mirtazapine | 82 | 34 |
| Clonazepam | Clonazepam | 81 | 13 |
| Xarelto | Rivaroxaban | 80 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 79 | 29 |
| Folic Acid | Folic Acid | 76 | 27 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 76 | 22 |
| Cefuroxime | Cefuroxime Axetil | 75 | 69 |
| Gemtesa | Vibegron | 75 | 28 |
| Finasteride | Finasteride | 74 | 24 |
| Aripiprazole | Aripiprazole | 73 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 71 | 23 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 71 | 24 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 13 |
| Methocarbamol | Methocarbamol | 67 | 41 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 67 | 30 |
| Meloxicam | Meloxicam | 66 | 32 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 65 | 20 |
| Sucralfate | Sucralfate | 65 | 30 |
| Dicyclomine Hcl | Dicyclomine Hcl | 62 | 33 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 61 | 51 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 60 | 28 |
| Glimepiride | Glimepiride | 59 | 19 |
| Januvia | Sitagliptin Phosphate | 59 | 18 |
| Spironolactone | Spironolactone | 58 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 57 | 20 |
| Ezetimibe | Ezetimibe | 56 | 25 |
| Allopurinol | Allopurinol | 54 | 23 |
| Naproxen | Naproxen | 54 | 33 |
| Temazepam | Temazepam | 54 | suppressed |
| Myrbetriq | Mirabegron | 53 | 13 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 51 | 38 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 51 | 13 |
| Azelastine Hcl | Azelastine Hcl | 49 | 19 |
| Donepezil Hcl | Donepezil Hcl | 49 | 19 |
| Enalapril Maleate | Enalapril Maleate | 49 | 14 |
| Hydrocortisone | Hydrocortisone | 48 | 33 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 48 | 15 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 48 | 21 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 47 | 15 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 47 | 12 |
| Atenolol | Atenolol | 46 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 46 | 22 |
| Entresto | Sacubitril/Valsartan | 46 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 22 |
| Propranolol Hcl | Propranolol Hcl | 45 | 14 |
| Vraylar | Cariprazine Hcl | 43 | 11 |
| Clotrimazole | Clotrimazole | 42 | 16 |
| Metformin Hcl Er | Metformin Hcl | 41 | 16 |
| Midodrine Hcl | Midodrine Hcl | 41 | 17 |
| Paxlovid | Nirmatrelvir/Ritonavir | 41 | 39 |
| Ammonium Lactate | Ammonium Lactate | 40 | 14 |
| Bupropion Hcl | Bupropion Hcl | 40 | 16 |
| Ibandronate Sodium | Ibandronate Sodium | 39 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 14 |
| Silver Sulfadiazine | Silver Sulfadiazine | 39 | 11 |
| Terbinafine Hcl | Terbinafine Hcl | 39 | 35 |
| Ondansetron Odt | Ondansetron | 38 | 30 |
| Lorazepam | Lorazepam | 37 | suppressed |
| Mupirocin | Mupirocin | 37 | 18 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 35 | 18 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 34 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 26 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | 13 |
| Lactulose | Lactulose | 33 | 18 |
| Rexulti | Brexpiprazole | 33 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 32 | 12 |
| Fluconazole | Fluconazole | 32 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | 12 |
| Rybelsus | Semaglutide | 32 | 12 |
| Metronidazole | Metronidazole | 31 | 27 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 31 | 17 |
| Ssd | Silver Sulfadiazine | 31 | 15 |
| Vascepa | Icosapent Ethyl | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Telmisartan | Telmisartan | 30 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | 11 |
| Glycopyrrolate | Glycopyrrolate | 29 | 15 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Cilostazol | Cilostazol | 27 | 14 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Dutasteride | Dutasteride | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Ramelteon | Ramelteon | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 18 | 11 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 14 |
| Ulticare Pen Needle | Pen Needle, Diabetic | 18 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Nabumetone | Nabumetone | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Prolia | Denosumab | 17 | 13 |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Ciclopirox | Ciclopirox | 16 | suppressed |
| Constulose | Lactulose | 16 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | 11 |
| Kerendia | Finerenone | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 15 | 13 |
| Topiramate | Topiramate | 15 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 14 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 14 | 14 |
| Bydureon Bcise | Exenatide Microspheres | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | 11 |
| Levofloxacin | Levofloxacin | 14 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 14 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 12 | suppressed |
| Famciclovir | Famciclovir | 12 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Incontrol Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Insulin Degludec Pen (U-200) | Insulin Degludec | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Tobramycin | Tobramycin | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,179.35 · 121 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, BREZTRI, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZEPBOUND, ZORYVE | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error